Biosensor could enable early Alzheimer's diagnosis

The group at the Universidad Politécnica de Madrid (UPM), has designed a new contrast agent for magnetic resonance imaging (MRI) based on functionalised magnetic nanoparticles that could work as a biomarker for an early diagnosis of this disease.

Alzheimer’s affects around 47 million people worldwide, but diagnostic techniques are currently limited to behavioural and neuropsychiatric evaluations, whilst a definitive diagnosis is only possible by analysing the brain of a patient after their death.

The Madrid group’s work could pave the way for new non-invasive methods that could enable far earlier diagnosis of the condition.

The technique focusses around the detection of iron deposits in the brain, which is one of the tell-tale signs of Alzheimer's disease.

Whilst MRI techniques are able to detect these deposits, it has hitherto only been possible to detect them when they are present in high concentrations, making it difficult to use the technique for early detection.

The UPM group has developed contrast agents that significantly boost the sensitivity for detecting these accumulations.